NO20056134L - Kombinasjon av en NMDA-reseptorantagonist og en selektiv serotoningjenopptaksinbibitor for behandling av depresjon og andre sinnsstemningsforstyrrelser - Google Patents
Kombinasjon av en NMDA-reseptorantagonist og en selektiv serotoningjenopptaksinbibitor for behandling av depresjon og andre sinnsstemningsforstyrrelserInfo
- Publication number
- NO20056134L NO20056134L NO20056134A NO20056134A NO20056134L NO 20056134 L NO20056134 L NO 20056134L NO 20056134 A NO20056134 A NO 20056134A NO 20056134 A NO20056134 A NO 20056134A NO 20056134 L NO20056134 L NO 20056134L
- Authority
- NO
- Norway
- Prior art keywords
- depression
- combination
- receptor antagonist
- nmda receptor
- mood disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47363903P | 2003-05-27 | 2003-05-27 | |
PCT/US2004/016959 WO2005000216A2 (en) | 2003-05-27 | 2004-05-27 | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20056134L true NO20056134L (no) | 2006-02-27 |
Family
ID=33551455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20056134A NO20056134L (no) | 2003-05-27 | 2005-12-22 | Kombinasjon av en NMDA-reseptorantagonist og en selektiv serotoningjenopptaksinbibitor for behandling av depresjon og andre sinnsstemningsforstyrrelser |
Country Status (16)
Country | Link |
---|---|
US (2) | US20050014743A1 (ru) |
EP (2) | EP1631274A4 (ru) |
JP (1) | JP2007500238A (ru) |
KR (2) | KR20060030469A (ru) |
CN (1) | CN1794981A (ru) |
AU (1) | AU2004251636B2 (ru) |
CA (1) | CA2528622C (ru) |
EA (1) | EA010430B1 (ru) |
IL (1) | IL172163A (ru) |
IS (1) | IS8150A (ru) |
MX (1) | MXPA05012493A (ru) |
NO (1) | NO20056134L (ru) |
RS (1) | RS20050851A (ru) |
UA (1) | UA80055C2 (ru) |
WO (1) | WO2005000216A2 (ru) |
ZA (1) | ZA200509542B (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7086532B2 (en) * | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
MXPA06002002A (es) * | 2003-08-21 | 2006-05-17 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y un inhibidor de transportador de glicina tipo 1 para el tratamiento de depresion. |
AR046314A1 (es) * | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
ITTO20050301A1 (it) * | 2005-05-05 | 2006-11-06 | Errekappa Euroterapici Spa | Formulazioni liquide orali contenenti citalopram |
US7884136B2 (en) * | 2005-06-27 | 2011-02-08 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
WO2007061868A2 (en) * | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
KR100769700B1 (ko) * | 2007-06-15 | 2007-10-23 | 손춘남 | 배압제거 역류방지 장치 |
US8877814B2 (en) * | 2007-09-12 | 2014-11-04 | Merz Pharma Gmbh & Co. Kgaa | Titration package for neramexane and its use in the treatment of an inner ear disorder |
US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
KR20110016891A (ko) * | 2008-05-09 | 2011-02-18 | 에모리 유니버시티 | 신경정신 장애의 치료를 위한 nmda 수용체 길항물질 |
TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類 |
US8399519B2 (en) | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
IT1396556B1 (it) | 2009-02-11 | 2012-12-14 | Serra | Uso di memantina per il trattamento di disturbi dell umore |
WO2010126527A1 (en) * | 2009-05-01 | 2010-11-04 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
US20120123166A1 (en) * | 2009-06-29 | 2012-05-17 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
US10576045B2 (en) * | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
AU2012307535A1 (en) * | 2011-09-13 | 2014-04-03 | Novartis Ag | Combinations comprising a S1P receptor modulator |
FR2983732B1 (fr) * | 2011-12-09 | 2013-11-22 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
KR101484405B1 (ko) * | 2013-08-14 | 2015-01-19 | 서울대학교산학협력단 | Ninjurin1 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물 |
JP2017514871A (ja) * | 2014-05-06 | 2017-06-08 | ノースウェスタン ユニバーシティ | Nmdar調節化合物の組合せ |
WO2016184900A1 (en) * | 2015-05-18 | 2016-11-24 | Sensorion | Calcineurin inhibitors of the setron family for the treatment of hearing loss |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
KR102089737B1 (ko) * | 2017-11-01 | 2020-03-16 | 한국화학연구원 | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH603545A5 (ru) | 1972-04-20 | 1978-08-31 | Merz & Co | |
DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
EP0392059B1 (de) | 1989-04-14 | 1993-09-15 | Merz & Co. GmbH & Co. | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie |
US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
DK0724432T3 (da) | 1993-10-22 | 2003-01-27 | Genentech Inc | Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner |
EP0980247A1 (en) * | 1997-05-07 | 2000-02-23 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
IL133235A (en) * | 1997-06-30 | 2004-02-19 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane nmda receptor antagonists and pharmaceutical compositions comprising them |
GB9802225D0 (en) * | 1998-02-02 | 1998-04-01 | Cerebrus Ltd | Chemical compounds |
DE69935331T2 (de) * | 1998-07-13 | 2007-10-31 | NPS Pharmaceuticals, Inc., Salt Lake City | Verfahren und verbindungen zur behandlung der depression |
SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
TW593223B (en) | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
AU2003210486B2 (en) * | 2002-01-16 | 2007-06-28 | Endo Pharmaceuticals Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
EP1551393A4 (en) * | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
AR042550A1 (es) * | 2002-12-23 | 2005-06-22 | Osmotica Argentina S A | Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina |
AR043467A1 (es) * | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
EP1734920A2 (en) * | 2004-02-13 | 2006-12-27 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
-
2004
- 2004-05-27 KR KR1020057022580A patent/KR20060030469A/ko not_active Application Discontinuation
- 2004-05-27 US US10/857,597 patent/US20050014743A1/en not_active Abandoned
- 2004-05-27 CA CA2528622A patent/CA2528622C/en not_active Expired - Fee Related
- 2004-05-27 KR KR1020077023390A patent/KR20070104480A/ko not_active Application Discontinuation
- 2004-05-27 EP EP04776170A patent/EP1631274A4/en not_active Withdrawn
- 2004-05-27 EP EP10175680A patent/EP2260844A1/en not_active Withdrawn
- 2004-05-27 MX MXPA05012493A patent/MXPA05012493A/es unknown
- 2004-05-27 JP JP2006533500A patent/JP2007500238A/ja active Pending
- 2004-05-27 AU AU2004251636A patent/AU2004251636B2/en not_active Ceased
- 2004-05-27 RS YUP-2005/0851A patent/RS20050851A/sr unknown
- 2004-05-27 WO PCT/US2004/016959 patent/WO2005000216A2/en active Application Filing
- 2004-05-27 UA UAA200512522A patent/UA80055C2/uk unknown
- 2004-05-27 CN CNA2004800143495A patent/CN1794981A/zh active Pending
- 2004-05-27 EA EA200501867A patent/EA010430B1/ru not_active IP Right Cessation
-
2005
- 2005-11-24 IL IL172163A patent/IL172163A/en not_active IP Right Cessation
- 2005-11-24 ZA ZA200509542A patent/ZA200509542B/xx unknown
- 2005-11-25 IS IS8150A patent/IS8150A/is unknown
- 2005-12-22 NO NO20056134A patent/NO20056134L/no not_active Application Discontinuation
-
2009
- 2009-11-20 US US12/592,171 patent/US20100076073A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IS8150A (is) | 2005-11-25 |
EP1631274A2 (en) | 2006-03-08 |
CA2528622C (en) | 2010-08-03 |
MXPA05012493A (es) | 2006-05-25 |
JP2007500238A (ja) | 2007-01-11 |
WO2005000216A8 (en) | 2005-12-22 |
ZA200509542B (en) | 2007-03-28 |
AU2004251636A1 (en) | 2005-01-06 |
CN1794981A (zh) | 2006-06-28 |
US20050014743A1 (en) | 2005-01-20 |
WO2005000216A3 (en) | 2005-11-10 |
EA200501867A1 (ru) | 2006-06-30 |
IL172163A (en) | 2012-01-31 |
KR20070104480A (ko) | 2007-10-25 |
EP2260844A1 (en) | 2010-12-15 |
CA2528622A1 (en) | 2005-01-06 |
US20100076073A1 (en) | 2010-03-25 |
WO2005000216A2 (en) | 2005-01-06 |
RS20050851A (sr) | 2008-04-04 |
EP1631274A4 (en) | 2007-03-28 |
KR20060030469A (ko) | 2006-04-10 |
EA010430B1 (ru) | 2008-08-29 |
UA80055C2 (en) | 2007-08-10 |
AU2004251636B2 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20056134L (no) | Kombinasjon av en NMDA-reseptorantagonist og en selektiv serotoningjenopptaksinbibitor for behandling av depresjon og andre sinnsstemningsforstyrrelser | |
EA200870424A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
EA201100133A1 (ru) | Антагонисты рецепторов простагландина d | |
CY1117317T1 (el) | Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων | |
EA200700262A1 (ru) | Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа | |
CY1119828T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν εκλεκτικους συνδετες υποδοχεα ντοπαμινης και μεθοδοι θεραπειας χρησιμοποιωντας εκλεκτικους συνδετες υποδοχεα ντοπαμινης | |
NO20056049L (no) | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds | |
NO20060402L (no) | 3-amino choman og 2-aminotetralinderivater | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
NO341523B1 (no) | Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse | |
ATE506065T1 (de) | Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen | |
NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
EA200602241A1 (ru) | Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение | |
NO20082125L (no) | Substituerte benzokondenserte derivater og deres anvendelse som vanilloidreseptorligander | |
EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
NO20065252L (no) | Behandling av forstyrrelser | |
NO20054371L (no) | Somatostatin-dopamin kimaere analoger | |
NO20060242L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin | |
EA200970583A1 (ru) | Способ получения пиперазиниловых и диазепаниловых производных бензамида | |
NO20074332L (no) | Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser | |
BR0313624A (pt) | Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória | |
DK1480627T3 (da) | Fremgangsmåder til mindskelse af angiogenese |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |